NCT04853823View on ClinicalTrials.gov

A Safety, Tolerability, and Dermal Reactogenicity Study of PDC-APB

PHASE1UnknownINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

November 1, 2021

Primary Completion Date

November 1, 2022

Study Completion Date

December 1, 2022

Conditions
Contact Dermatitis
Interventions
DRUG

PDC-APB

PDC-APB Intra-muscular Injection

OTHER

Placebo

Vehicle

Sponsors
All Listed Sponsors
collaborator

Milton S. Hershey Medical Center

OTHER

lead

Hapten Sciences, Inc.

INDUSTRY